RATIONALE: Giving chemotherapy, such as cyclophosphamide and fludarabine, before a donor
stem cell transplant helps to remove the patient's cells to allow for the transplant cells
to take and grow. It also helps stop the patient's immune system from rejecting the donor's
stem cells. When the healthy stem cells from a donor are infused into the patient, they may
help the patient's bone marrow make stem cells, red blood cells, white blood cells, and
platelets. Sometimes the transplanted cells can make an immune response against the body's
normal cells. Giving antithymocyte globulin and removing the T cells from the donor cells
before transplant and giving cyclosporine before and after transplant may stop this from
happening.
PURPOSE: This phase I/II trial is studying the side effects of cyclophosphamide,
fludarabine, and antithymocyte globulin followed by donor stem cell transplant and to see
how well it works in treating patients with Fanconi anemia.

Clinical Details

Official title: A Study of Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed by Matched Sibling Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia

through day +30 or for 7 days after engraftment, whichever day is later, if no acute
GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil
count [ANC] > 0. 5 x 10^9/L.
After completion of study therapy, patients are followed periodically.

Eligibility

Minimum age: N/A.
Maximum age: 59 Years.
Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients must be <60 years of age with a diagnosis of Fanconi Anemia (FA).